DiaMonTech AG

  • WKN: A255G4
  • ISIN: DE000A255G44
  • Land: Deutschland

Nachricht vom 28.10.2019 | 08:00

DiaMonTech plans IPO to finance growth

DGAP-News: DiaMonTech GmbH / Key word(s): IPO

28.10.2019 / 08:00
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.


DiaMonTech plans IPO to finance growth

  • Medical technology company with unique laser-based technology for high-precision, non-invasive blood glucose monitoring
  • Clinical study has confirmed accuracy of DiaMonTech's non-invasive blood glucose monitoring method
  • Market launch of a smartphone-sized measuring device planned for the end of 2020
  • Global market volume for blood glucose monitoring systems is in excess of 10 billion US dollars
  • Offering of new shares from a capital increase in the amount of approx. 50 million euros as well as a greenshoe option in the amount of 15 percent of the offering
  • Proceeds from the IPO shall be invested in particular in the further product development, the start of serial production as well as marketing and sales
  • Listing planned on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

Berlin, 28 October 2019 - DiaMonTech GmbH ("DiaMonTech" or the "Company"), a young and innovative medical technology company, intends to go public on the Frankfurt Stock Exchange (Prime Standard) within the next three months, subject to capital market conditions.

Thorsten Lubinski, CEO of DiaMonTech
: "We are on the brink of making it possible for diabetics worldwide to measure their blood glucose level precisely and non-invasively for the first time ever. With our new product 'D-Pocket', daily pricking will not be necessary for them anymore. So we will be setting an unrivaled standard in one of the most attractive growth markets with currently more than 400 million diabetics".

"We plan to use the IPO proceeds for the market launch of this device as early as 2020 and are able to add momentum to the corresponding preparations", adds Enrico Just, CFO of DiaMonTech.

Unique laser-based technology for precise non-invasive blood glucose measurement

DiaMonTech has developed a laser-based diagnostic method that allows the precise measurement of blood glucose without finger pricking, blood or pain. With the innovative photothermal detection technology, it is possible to precisely determine the blood glucose level by just placing a finger on an optical interface for a few seconds.

The recently published study results ("Study 100") confirmed the accuracy of the proprietary method for non-invasive blood glucose monitoring. In the study, the blood glucose level of 100 volunteers was measured using DiaMonTech's laser-based, non-invasive technology as well as a clinically established invasive reference method. The non-invasive method yielded 99.1 percent precise measurement results. Such a high accuracy has only been achieved with (minimally-) invasive devices.

DiaMonTech holds a strong IP position with comprehensive patents and patent applications. These are the result of more than 20 years of scientific research carried out by Prof. Dr. Werner Mäntele, one of the founders and the largest shareholder of the company.

Novel mobile measuring devices before market launch
DiaMonTech's first device for non-invasive blood glucose monitoring "D-Base" is CE certified as medical product since March 2019. It is optimized for the application in business environments such as diabetes centers or pharmacies and is used for demonstration purposes.

In addition, DiaMonTech is currently finalizing development of the "D-Pocket" product, which is planned to be launched on the market by the end of 2020. The device has the size of a smartphone, allowing the users to determine their blood glucose level accurately and painlessly anytime, anywhere, as often as they want. In a next development step, the Company plans to introduce an even smaller version of its the non-invasive blood glucose monitoring solution ("D-Band") suitable for integration into other portable electronic devices such as fitness and health trackers or smartwatches. This would allow to monitor the blood glucose level continuously without having to think about it.

DiaMonTech intends to distribute the device "D-Pocket" directly as well as via selected sales partners in Europe and indirectly via distributors in selected markets outside Europe. DiaMonTech has already signed letters of intent with potential distributors for the regions China and Asia-Pacific as well as Japan for the sale of 110,000 units per year.

Furthermore, the Company has signed an agreement with one of the three largest health insurance companies in Germany, according to which both partners intend to collaborate regarding future products, including the "D-Pocket". The objective is to develop new treatment opportunities and optimize current processes. In addition, the Company signed a letter of intent with the Deutscher Apothekerverband e.V. (German Pharmacists' Association, "DAV"), according to which the parties intend to enter into a strategic partnership for the distribution of non-invasive measuring devices in pharmacies.

Versatile platform technology offers additional revenue potential
In the future, DiaMonTech's innovative photothermal detection technology platform shall also be applied in other fields. Beyond glucose measurement, the photothermal detection technology platform can be used for the detection and quantitative analysis of molecules in liquids and soft matter. In the medium term, the Company plans to expand the usage of the photothermal technology platform. The product pipeline comprises devices for the real-time analysis of blood or urine or for purposes of real-time therapeutic drug monitoring as well as devices for blood analysis at home or the constant monitoring of other biomarkers such as lactate. Furthermore, the technology is also suitable for the analysis of components in process fluids used in industrial production.

Attractive target market - Global market volume for blood glucose monitoring devices to exceed 10 billion US dollars in 2019
DiaMonTech initially focuses on the field of diabetes, targeting a highly attractive, well-developed market that quickly adopts new products.

In 2017, there were 425 million diabetes patients worldwide.1 The global market volume for blood glucose monitoring systems is expected to reach approximately 10.8 billion US dollars in 2019.2 Experts assume that the non-invasive segment will reach around 2.4 billion US dollars by 2026. This corresponds to an annual growth rate (CAGR) of 121.5 percent for the period 2019 to 2026.3 The user-friendly characteristics of these instruments are a key reason driving the strong growth in this segment.

IPO to finance growth
The planned offer on the Frankfurt Stock Exchange (Prime Standard) shall consist of newly issued ordinary bearer shares with no-par value resulting from a capital increase against contribution in cash. The capital increase is expected to amount to around 50 million euros. In addition, it is planned to grant an over-allotment option of 15 percent, which is also expected to be carried out with new shares.

The Company intends to invest the IPO proceeds in the planned growth and use the funds in particular for the further development of the "D-Pocket", the start of serial production as well as marketing and sales.

MainFirst Bank AG is acting as Sole Global Coordinator and Sole Bookrunner.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal detection technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.DiaMonTech.de/home

Press Contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-Mail DiaMonTech@kirchhoff.de

Sources
1 IDF Atlas, 2017
2 Fortune, 2019
3 Fortune, 2019

Disclaimer:
The information contained herein is not for distribution, directly or indirectly, in or into the United States of America (including its territories and possessions of any State of the United States of America or the District of Columbia) and must not be distributed to U.S. persons (as defined in Regulation S of the U.S. Securities Act of 1933, as amended ("Securities Act")) or publications with a general circulation in the United States of America. This publication constitutes neither an offer to sell nor a solicitation to buy or subscribe to securities in the United States of America. Securities of DiaMonTech GmbH (the "Company") have not been and will not be registered under the Securities Act and may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act. The Company does not intend to register any portion of the offering in the United States of America or to conduct a public offering of the securities in the United States of America.

This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. No offer of the securities of the Company is being, or will be made, to the public outside the Federal Republic of Germany ("Germany").

The offer in Germany will be made solely by means of, and on the basis of, a securities prospectus for the purposes of Regulation (EU) 2017/1129 as amended (the "Prospectus Directive") to be approved by the German Federal Financial Supervisory Authority (BaFin). After the approval the securities prospectus will be available free of charge at the Company's office, as well as, for viewing in electronic form, on the Company's website http://www.DiaMonTech.de/home. An investment decision regarding the publicly offered securities of the Company should only be made on the basis of the securities prospectus.

In member states of the European Economic Area ("EEA") other than Federal Republic of Germany ("Germany"), this information is only addressed to and directed at persons who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Directive ("Qualified Investors").

In the United Kingdom, this information is directed at and/or for distribution only to (i) investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,as amended (the "Order"), or (ii) high net worth companies falling within article 49(2)(a) to (d) of the Order (each such person hereinafter a "relevant person"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this information or any of its contents.

Statements contained herein may constitute "forward-looking statements." Forwardlooking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate", "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forwardlooking statements. You should not place undue reliance on forward-looking statements and the Company does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.



28.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

MPH Health Care AG

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Buy

20. September 2021